Convulsive status epilepticus management in adults and children: Report of the Working Group of the Polish Society of Epileptology by Jędrzejczak, J. et al.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 1 9 – 4 2 6
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns[1_TD$DIFF]GuidelinesConvulsive status epilepticus management in
adults and children: Report of the Working Group
of the Polish Society of EpileptologyJ. Jędrzejczak a, M. Mazurkiewicz-Bełdzińska c, M. Szmuda c,
B. Majkowska-Zwolińska d, B. Steinborn e, D. Ryglewicz f,
R. Owczuk g, A. Bartkowska-Śniatkowska h, E. Widera i,
K. Rejdak j, M. Siemiński k, E. Nagańska b,*
aDepartment of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland
bDepartment of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of
Sciences, Warsaw, Poland
cDepartment of Developmental Neurology, Chair of Neurology, Medical University of Gdańsk, Poland
dCentre for Epilepsy Diagnosis and Treatment, Foundation of Epileptology, Warsaw, Poland
eDepartment of Developmental Neurology, Poznan Univerity of Medical Sciences, Poznań, Poland
f 1st Neurological Department, Institute of Psychiatry and Neurology, Warsaw, Poland
gDepartment of Anaesthesiology and Intensive Therapy, Medical University of Gdansk, Poland
hDepartment of Paediatric Anaesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznań,
Poland
iClinic of Pediatrics and Neurology of Developmental Age, Medical University of Silesia, Katowice, Poland
jDepartment of Neurology, Medical University of Lublin, Poland
kDepartment of Emeregency Medicine, Medical University of Gdansk, Polanda r t i c l e i n f o
Article history:
Received 20 March 2018
Accepted 11 April 2018






a b s t r a c t
Introduction: TheWorking Group was established at the initiative of the General Board of the
Polish Society of Epileptology (PSE) to develop an expert position on the treatment of
convulsive status epilepticus (SE) in adults and children in Poland. Generalized convulsive
SE is the most common form and also represents the greatest threat to life, highlighting the
importance of the choice of appropriate therapeutic treatment.
Aim of guideline: We present the therapeutic options separately for treatment during the
early preclinical (>5–30 min), established (30–60 min), and refractory (>60 min) SE phases.
This division is based on time and response to AEDs, and indicates a practical approach
based on pathophysiological data.
Results: Benzodiazepines (BZD) are the ﬁrst-line drugs. In cases of ineffective ﬁrst-line
treatment and persistence of the seizure, the use of second-line treatment: phenytoin,
obarbital is required. SE that persists after the administration of
phenytoin or another second-line AED at appropriate doses is deﬁnedvalproic acid or phen
benzodiazepines and* Corresponding author.
E-mail address: kl.neurologii@szpital-orlowskiego.pl (E. Nagańska).
https://doi.org/10.1016/j.pjnns.2018.04.002
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
as refractory and drug resistant and requires treatment in the intensive care unit (ICU). EEG
monitoring is essential during therapy at this stage. Anesthesia is typically continued for an
initial period of 24 h followed by a slow reversal and is re-established if seizures recur.
Anesthesia is usually administered either to the level of the ‘‘burst suppression pattern’’ or
to obtain the ‘‘EEG suppression’’ pattern.
Conclusions: Experts agree that close and early cooperation with a neurologist and anesthe-
tist aiming to reduce the risk of pharmacoresistant cases is an extremely important factor in
the treatment of patients with SE. This report has educational, practical and organizational
aspects, outlining a standard plan for SE management in Poland that will improve thera-
peutic efﬁcacy.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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General Board of the Polish Society of Epileptology (PSE) to
develop an expert position on the treatment of convulsive
status epilepticus (SE) in adults and children in Poland. For
many years the PSE has promoted the highest standards of
medical care. However, there are few updated papers on
management and treatment of SE in Polish literature [1–4].
The development and preparation of these recommenda-
tions is a vital contribution for patients with epilepsy in
Poland, and nowmust be translated into daily clinical practice.
Physicians, particularly neurologists and neurosurgeons need
to be familiar with SE. The generalized convulsive SE is one of
the most common life-threatening conditions that requires a
prompt rescue therapy in order to prevent from further
consequences. Prolonged and/or repetitive tonic–clonic sei-
zures involving a whole body are extremely exhausting and
lead to the energy crisis. Besides, the longer the seizure lasts,
the lower probability of self-limitation and adequate response
to an antiepileptic rescue treatment. All of above factors plus
in addition unknown cause of the GTCS (for example amedical
origin), lead to the higher morbidity in this emergency
situation.2. Purpose of this report
SE treatment should proceed in accordance with familiar and
well-understood procedures, but should also be updated and
supplemented with new information. Recommendations for
SE developed by the European Federation of Neurological
Societies (EFNS) as well as the Report of the Guideline
Committee of the American Epilepsy Society 2016 have
recently been published [5,6], and the new deﬁnitions and
classiﬁcations for SE were developed by the International
League Against Epilepsy (ILAE) [7]. Our report has educational,
practical and organizational aspects, outlining a standard plan
for SE management in Poland that will further improve
therapeutic efﬁcacy.
It is also crucial to elaborate a therapeutic treatment
protocol for neurologists and anaesthesiologists, ideally
available in every neurological and anesthesia ward.2.1. Methods
The expert opinionpresented in this paper is based on a review
of the current literature regarding strategies for seizure
disorder management as well as the clinical experience and
good medical practice of clinicians with extensive back-
grounds in the area. Each of the panelists provided comments
and made remarks, and the version presented here was
developed after reaching consensus.
3. Deﬁnitions of termsAccording to Trinka et all 2015 ‘‘Status epilepticus is a
condition resulting either from the failure of the mechanisms
responsible for seizure termination or from the initiation of
mechanisms, which lead to abnormally, prolonged seizures
(after timepoint t1). It is a condition,which canhave long-term
consequences (after time point t2), including neuronal death,
neuronal injury, and alteration of neuronal networks, depend-
ing on the type and duration of seizures’’ [7].
Clinical trials suggest that a single seizure seldom lasts
longer than 2 min, therefore we assume that the generalized
seizures in SE include all cases of seizure lasting >5 min, or 2
seizures without baseline recovery. This ‘‘operational’’ deﬁni-
tion indicates the necessity of immediate pharmacological
treatment for all patients with prolonged seizures over 5 min
[5–10]. It should be pointed that in the case of convulsive
(tonic–clonic) SE, both time points (t1 at 5 min and t2 at 30 min)
are based on animal experiments and clinical research. This
evidence is incomplete, and there is furthermore considerable
variation, so these time points should be considered as the
best estimates currently available [7].
Refractory SE is deﬁned as no response to a benzodiazepine
plus an anti-seizure drug [11].
Super-refractory SE is a stage of refractory SE characterized
by unresponsiveness to initial anesthetic therapy and is
deﬁned as ‘‘SE that continues or recurs 24 h or more after
the onset of anesthesia, including those cases in which SE
recurs on the reduction or withdrawal of anesthesia.’’ [11].
Super-refractory SE can also be deﬁned as SE that has
continued or recurred despite 24 h of general anesthesia [12].
The new clinical syndrome deﬁned as new-onset refractory
status epilepticus (NORSE) refers to patients with acute brain
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occurs without any apparent cause [5–10], so it still requires
the extensive studies to determine the etiology as that
increases the odds of a more favorable outcome.
4. SE epidemiology, etiology and mortalityIn general, SE incidence varies from 9.9 to 41/100,000 per year
[12] with a bimodal age distribution. The youngest and oldest
patients suffer from SE most often, speciﬁcally those in the
ﬁrst decade of life (14.3/100,000) and those over 60 years of age
(28.4/100,000) [13–15]. A signiﬁcant percentage of patients with
SE in both pediatric (16–38%) and adult populations (42–50%)
have a history of diagnosed epilepsy [16].
Etiology of status epilepticus could be different, namely:
cerebrovascular, hemorrhagic stroke, symptomatic, toxic and
metabolic, infectious, autoimmunologic, posttraumatic, or
non-compliance. Cerebrovascular pathologies are considered
to be the basic etiologic factors in adults, especially hemor-
rhagic stroke (38%) [17–19].
Reports of mortality related to SE varies. Koubeissi found a
prevalence of 3.45% in a very large population of over 11,500
patients with generalized convulsive SE aged from 13 to 64
years. Short-term mortality over a period of 30 days from the
SE episode varied between 7.6 and 22% in all groups, but was
the highest in the oldest group [20,21]. This frequency
increased signiﬁcantly in a subgroup of mechanically venti-
lated patients. SE prevalencewas lower in adults under the age
of 60 than in children, but mortality is higher. Mortality rates
were 26% in adults under the age of 60, 40% in patients over 80,
and 5–8% in children [16,17].
5. The outcome of the PSE Working Group on
the treatment of convulsive SE in adults and
children in PolandThe goal of therapeutic management for SE is to stop the
electrographic discharges as quickly as possible, and conse-
quently protect neurons from damage. The diagnostic and
therapeutic procedures for children adults are similar, but the
medication dosages should be adjusted accordingly.
SE duration prior to starting treatment inﬂuences its effect,
regardless of the type of medication, and seizure control
following pharmacological treatment is inversely related to SE
duration prior to treatment.
We present the therapeutic options separately for treat-
ment during the early preclinical (>5–30 min), established (30–
60 min), and refractory (>60 min) SE phases. This division is
based on time and response to AEDs, and indicates a practical
approach based on pathophysiological data.6. Management of initial SE (>5–30 min)
6.1. Preclinical and ﬁrst-line treatment
SE requires immediate and effective treatment [6,7,22]. The
abnormal discharge of the cortical neurons during convulsiveseizure results in the loss of inhibitory synaptic transmission
mediators (GABA, glutamate) and pathologically increased
neuronal activity. On the other hand, brain trauma, intoxica-
tion or infections also increase neuronal excitability and
impaired mechanism of seizure termination. In time, the
longer the seizure lasts, the natural mechanisms of self-
limitation fail and lead to the further neuronal damage.
Extremely important is to start rescue therapy and achieve
seizure cessation before this pathophysiologic process devel-
ops. Therefore, expendable delay in implementation of
emergency drugs may result in ﬁnal ineffectiveness of
introduced antiepileptic medication.
Benzodiazepines (BZD) are the ﬁrst-line drugs, and act as
GABA receptor agonists [7,15,22]. These drugs are preferred
primarily due to the rapid onset of action and high efﬁcacy for
controlling seizures [23]. In cases of prolonged convulsive
seizure in patients with diagnosed epilepsy, a family member
or caregiver may give diazepam by the rectal route before the
arrival of emergency services. Many patients with diagnosed
epilepsy in Poland and a history of prolonged seizures or
previous SE are prescribed diazepam in this form. Diazepam is
available in doses of 5 mg and 10 mg, and an additional 10 mg
per rectal dosemay be repeated if seizure persists. In children,
5 mg (>10 kg, age 1–3 years) or 10 mg (>15 kg, age >3 years) is
recommended, depending on age and body weight. This dose
can be repeated if necessary, at 5 mg in younger children and
10 mg in older children. Administration of the drug to very
young children (<1 or over<10 kg) is not recommended by the
manufacturer.
Midazolam is marketed under the trade name Buccolam
and available in the form of pre-ﬁlled oral syringes, the
solution is absorbed through the mucosa of the inner side of
the cheek.Midazolamused at a dose of 0.5 mg/kg is as effective
and safe as rectally administered diazepam, and is easier to
use with a shorter half-life. There are also intranasal forms of
midazolam, which are administered at a dose of 0.2 mg/kg and
also have greater efﬁcacy and safety than rectal diazepam. The
preparation is registered in Poland for use in children from 3
months to 18 years of age only, but it is not currently produced
in Poland and must be imported.
The rectal form of diazepam, nasal form of midazolam, or
buccal midazolam can be used as alternative initial therapies
(level B) in prehospital settings. The initial therapy should be
administered as a single full dose, rather than small multiple
doses, and should not be administered twice with the
exception of IV lorazepam and diazepam (one-time repeat
of the full dose) (level A, 2 class I tests, one class II RCT). There
was no signiﬁcant difference in efﬁcacy between IV lorazepam
and IV diazepam in children with SE (level A). Midazolam (IM/
nasal/buccal) is probably more effective than diazepam (IV/
rectal, level B) for children [6,28–30].
6.2. Emergency service and pharmacological treatment
After reaching the patient during prolonged tonic–clonic
seizure or SE, the task of emergency services is to either
obtain information from thewitnesses regarding the seizure or
to estimate the duration, potential cause, accompanying
diseases including epilepsy, circumstances of the seizure,
provocative factors, medications or missed doses, exposure to
Table 1 – General support/monitoring of SE.
All drugs should be administered intravenously (IV) by two-way procedure:
 Introduction of a cannula into a vein to collect blood for diagnostic testing for the causes of SE including biochemical testing and AED level
determination.
 Introduction of a second cannula into the vein for AED administration. The injection should be maintained by administering saline
solution, and glucose solution should not be administered because of the possibility of AED precipitation, especially when using phenytoin.
 Vital function monitoring, stabilization of respiratory and circulatory functions, and blood pressure control. Glucose should be
administered only in cases of documented hypoglycemia in a bolus of 50 ml 50% glucose for adults and 2 ml/kg 25% glucose for children. It is
worth noting that hyperglycemia may exacerbate neuronal damage. 100 mg of thiamine can be given IV for chronic alcoholics or addicts
before or simultaneously with the administered glucose
 Body cooling if the temperature is high.
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aspiration, and potential injuries that precede or result from
the seizure itself.
At the same time, the requirements include the urgent
need to estimate airway patency and cardiorespiratory
efﬁciency including the assessment of saturation, heart rate,
blood pressure, and ECG, and implementation of oxygen
therapy. Adequate ventilation is maintained in most patients
with SE, provided that the airways are not obstructed. The
insertion of an oropharyngeal tube and administration of
oxygen through a nasal mustache or ventilation with the
Ambu bag typically provide adequate oxygenation, and
intravenous access is recommended (Table 1).
Immediate ﬁrst line treatment should be introduced
simultaneously. Benzodiazepines are the ﬁrst line treatment





Miazepam: intravenously (IV) administered slowly at a
dose of 10–20 mg in adults (the dose may be repeated) or
0.2–0.3 mg/kg in children (or 1 mg for each year of life),
administered slowly at 2–5 mg/min. It reaches the appro-
priate concentration in the CNS after approximately 1 min
by IV administration, and the maximum concentration
occurs within 15 min of dosing. It is metabolized in the
liver to the active metabolites oxazepam, temazepam, and
demethyldiazepam, which prolongs the duration. The
half-life of diazepam is approximately 48 h [23–26].(b) Clonazepam: IV administered in a single dose of 1 mg in
adults and 0.5 mg in children. The speed of IV injection in
adults should not exceed 0.25–0.5 mg per minute. It should
be noted that this drug has not been included in the current
international guidelines for the treatment of SE, however
in our experience it is efﬁcacious and widely available in
Poland.able 2 – First line treatment.
rug Dosage
iazepam Iv 10–20 mg in adults, 02, 03 mg/kg in
children
onazepam Iv 1 mg in adults, 0.5 mg in children
razepam Iv 0.05–0.1 mg/kg
idazolam Iv 2.5 mg <1 year, 5 mg, 1–5 years old,
7.5 mg, 5–10 years, 10 mg in 10–18 and
adults
Im 0.2 mg/kg(c) Lorazepam: commonly used in the USA and in many
European countries. The recommended IV dosage of is
0.05–0.1 mg/kg (typically 4–8mg) for 2–5min. If the seizure
persists after 10min, another 4mg IV is recommended
[5,6,25,26]. The IV form of lorazepam is not registered in
Poland.(d) Midazolam is administered to control SE, and is available
for either IV administration or IM injection. IV dosage age
2.5 mg for children <1 year old, 5 mg for children 1–5 years
old, 7.5 mg for children from 5 to 10 years, and 10 mg for
children aged 10–18 years and older patients (0.1–0.2 mg/kg
IV) or 0.2 mg/kg IM [25,27].
According to the Report of the Guideline Committee of the
American Epilepsy Society (2016), IM midazolam, IV loraze-
pam, or IV diazepam are recommended as the initial therapies
of choice, based on demonstrated efﬁcacy, safety, and
tolerability (level 1, 4 studies of class I RCTs). IV phenobarbital
may be an alternative initial therapy, but is not the ﬁrst choice
drug (level A, one class I RCT test) [6].
Adverse effects of benzodiazepines such as sedation and
respiratory depression up to apnea, especially if the drug is
administered too quickly or if the dosage is exceeded [15].
Therefore, it is extremely important to determine whether
caregivers administered benzodiazepines earlier and whether
the patient took benzodiazepines in oral formbefore the onset of
the prolonged seizure. IV benzodiazepines should be adminis-
tered in a slow infusion and the patient should be closely
monitored during parenteral administration. The availability of
the resuscitation kit should be always veriﬁed [5,7,14,15], and it
should be emphasized that if it is not possible to determine the
timeof SE onset in apatientwhohasnot beenpreviously treated,
the patient should receive ﬁrst-line treatment.
Patients should be transported to the nearest Emergency
Department in hospital with a neurological ward.
Expert opinion suggests the necessity of increasing the availability
of lorazepam in Poland, which penetrates vascular tissues more
slowly, and has a longer therapeutic effect and a lower risk of
accumulation in organs (lesser risk of cardiovascular depression).7. Management of established SE (30–60 min)
7.1. Second-line treatment
Established SE is diagnosed in cases of ineffective ﬁrst-line
treatment and persistence of the seizure, requiring the use of
Table 3 – Second line treatment.
Drug Dosage
Phenytoin Iv infusion 20 mg/kg (max rate 25 mg/min)
Valproic acid Iv 20–40 mg/kg (max rate 6 mg/kg/min)
Phenobarbital Iv 20 mg/kg (max rate 50 mg/min)
Chloral hydrate Pr 0.3–0.5 ml/kg
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setting.
These medications are recommended for second-line SE
treatment (Table 3):(a) Phenytoin: is a well-known and widely accessible antiepi-
leptic drug. It's mechanism of action is inhibition of
sodium channels. By working on intracellular part of the
ion channel it decreases the inﬂow of sodium into the cell,
which result in reduction of excitability of cortical neurons.
Stabilizes the cellmembrane of central neurons. Phenytoin
is insoluble in water and requires an alkaline solvent to
prevent from precipitation. This alkalinity is responsible
for rather mild adverse events, such as skin irritation,
thrombophlebitis or local tissue necrosis. Purple glove
syndrome (triad of edema, discolouration and pain distally
to injection site) is uncommon and mild. However,
phenytoin increases a risk of cardiac arrhythmias as well
as hypotension. Therapeutic level ranges vary between 10
and 20 mg/ml. Overdose is manifested by horizontal
nystagmus. Phenytoin is perfectly suited for quick seizure
control as well as chronic therapy [24,25,31], reaches
maximum concentration in the cerebrospinal ﬂuid after
20 min, and has a half-life is 24 h which may be prolonged
by high concentrations of phenytoin in the blood. The
concentration in brain tissue is 3–4 times higher than in
blood and lasts for several hours. Phenytoin is adminis-
tered in an infusion pump as an continuous intravenous
infusion of 20 mg/kg (at a maximum rate of 25 mg/min).
Administration should begin quickly and the ﬂow should
be adjusted in order to stop the seizures. It should then be
brought to a daily dose that will provide the therapeutic
concentration of the drug in the blood serum, this typically
takes a few days and the daily dose of 2000 mg/24 h should
not be exceeded. The drug can then be administered orally
[15,23,24,32]. The beneﬁts of phenytoin include the long-
lasting effects, rapid achievement of high-level concentra-
tion in the cerebrospinal ﬂuid, wide availability, and many
years of experience associated with its application.(b) Phenytoin shouldnot be administered in a glucose solution
due to the precipitation of microcrystals. Blood pressure
and ECG should bemonitored during phenytoin treatment,
and patients with impaired renal and hepatic function
should have the phenytoin-free fraction monitored.
Cardiovascular system monitoring is necessary due to
the possibility of hypotension (27%) and bradyarrhythmia
(7%). Other side effects of phenytoin include ‘‘purple glove
syndrome’’ characterized by edema, discoloration, and
pain distal to the injection site, as well as the possibility of
inducing sterile abscesses at the injection site. There is
little data conﬁrming safe use of phenytoin in the elderly
population (due to the possible negative impact ofphenytoin on the cardiovascular system and sometimes
undesirable neuroprotective effect of the drug). Phenytoin
may be substituted by fosphenytoin, a phenytoin prodrug,
administered by IV or IM. Although fosphenytoin has fewer
adverse effects than phenytoin, particularly a reduced risk
of local irritation, it is not currently available or used in
Poland [15,32,33]. IV valproic acid (VPA) at a dose of 20–
40 mg/kg may also be used at a speed of 6 mg/kg/min. The
results of more than 20 published studies (both retrospec-
tive and prospective) in children and adults including over
500 patients suggest that VPA is as effective as phenytoin
for the treatment of SE that cannot be controlled by
benzodiazepines. This data can be found in the Report of
the Guideline Committee of the American Epilepsy Society
(level B, one study class II) [6]. Valproate does not induce
hypotension, respiratory depression, or severe sedation.
Intravenous valproate is considered to be a therapeutic
option especially in patients with cardiovascular diseases.
Although the precise mechanism of action is not known,
several mechanisms have been suggested. VPA may
potentiate postsynaptic GABA, inhibit GABA-transaminase
and succinic acid decarboxylase, and/or increase glutamic
acid decarboxylase. Itmay also block voltage-gated sodium
channels to limit depolarization-induced, sustained repet-
itive ﬁring and may block low-threshold T-type calcium
channels. Many consensus guidelines recommend the use
of VPA as an alternative second-line treatment. Reports on
SE unresponsive to ﬁrst-line agents have generally noted
successful termination of seizures following intravenous
VPA. If given in large doses and by rapid infusion, VPA
rarely causes cardiovascular toxicity such as hypotension
or arrhythmia. However, VPA can cause coagulopathies
such as platelet dysfunction, thrombocytopenia, and
hypoﬁbrinogenemia. Although rare, pancreatitis or DRESS
syndrome has been noted after VPA. Important to note is
that VPA is a cytochrome P450 inhibitor, thus interacts
with many other medications, similar to phenytoin. This
agent is particularly problematic in patients with inborn
errors of metabolism, such as ornithine carbamyltransfer-
ase deﬁciency. Valproic acid is administered as 20–40 mg/
kg IV over 10 min, and an additional 20 mg/kg can be given
if the patient is still seizing. The goal blood level is 100 mg/
mL, and can be drawn immediately after the loading dose
has been administered. Maximum dose of 3 g. [34](c) Phenobarbital: administered at a rate of 20 mg/kg, with a
maximum speed of administration up to 50 mg/min.
Phenobarbital has historically been used for benzodiaze-
pine – resistant SE. According to the Report of the Guideline
Committee of the American Epileptic Society, IV pheno-
barbital is treated as an alternative therapy due to side
effects (level B, one class II test). There are also reports
indicating that up to 20% of patients who have clinically
resolved symptoms of SE after applying phenobarbital
have persistent electrographic features of SE [5,7,35].
Phenobarbital binds to inhibitory GABA-A receptors. It
leads to the increased duration of the chloride channels
opening. It also inhibits sodium and calcium channels at
the AMPA receptor to reduce the release of glutamate.
Therapeutic dose should range from 20 to 30 mg/kg. In
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cheap and the efﬁcacy in seizure cessation is fairly enough
in established generalized convulsive SE. However, it is a
cytochrome P450 inducer, therefore it interacts with many
medications and has a worse side effect proﬁle, with a
propensity to cause hypotension, sedation, and respiratory
depression, particularly during rapid infusion. Phenobar-
bital should be given as a bolus of 10–20 mg/kg IV at a rate
of 50–100 mg/min, up to a total amount of 700 mg in about
seven min. Patients must have their respiration and blood
pressuremonitored while they are receiving the bolus [34].(d) Chloral hydrate is another older drug that could be
considered, especially in situations with no intravenous
option. It is applicated per rectum, in a dose of 0.3–0.5 ml/
kg dissolved 1:1 in vegetable oil, and can be repeated after
20 min [34].
Speciﬁc treatments for brain edema (e.g. mannitol or
steroids) are indicated in select cases only, depending on
the patient's clinical condition. Use of these treatments
requires a careful assessment of potential contraindications.
Experts agree that the treatment of established SE should be
performed in the neurological ward.
8. Management of refractory SE (>60 min)SE that persists after the administration of benzodiazepines
and phenytoin or another second-line AED at appropriate
doses is deﬁned as refractory and drug resistant and requires
treatment in the intensive care unit (ICU). EEG monitoring is
essential during therapy at this stage [5,7].
The optimal anesthetics for use in pharmacological coma
are still unknown. The drugs most commonly used for this
purpose include pentobarbital, thiopental, propofol, and
midazolam, which appear to have similar efﬁcacies as
reported in the literature [5,7,26,27] (Table 4). The choice of
anesthesia depends largely on side effect considerations [36].
Propofol is the easiest anesthetic to use from a pharmacoki-
netic and pharmacologic point of view, and pentobarbital and
thiopental are the most difﬁcult. Propofol carries a particular
risk of propofol infusion syndrome characterized by: hypoten-
sion, bradyarhythmias, heart failure, hyperkalemia, hepato-
megaly, lipemia, metabolic acidosis, and rhabdomyolysis
[34,36] and midazolam is associated with a particular risk ofable 4 – Dosage of anesthetics for SE treatment.
rug Dosage
iopental - 3–5 mg/kg IV bolus, additional doses
1–2 mg/kg, repeated every 2–3 min until
seizures controlled
- maintenance at 3–7 mg/kg/min
ntobarbital - 10–15 mg/kg IV bolus
- maintenance at 0.5–1 mg/kg/h
idazolam - 0.2 mg/kg IV bolus
- maintenance at 0.05–0.4 mg/kg/h
opofol - 2–3 mg/kg IV bolus, additional doses
1–2 mg/kg repeated until seizures
controlled
- maintenance at 2–10 mg/kg/hacute tolerance. All three anesthetics carry the serious side
effects of hypotension and cardiac depression.
Anesthesia is typically continued for an initial period of
24 h followed by a slow reversal. Anesthesia is re-established if
seizures recur. Aesthesia is usually administered either to the
level of the ‘‘burst suppression pattern’’ or to obtain the ‘‘EEG
suppression’’ pattern, however, complete suppression of EEG
activity is associated with a higher risk of hypotension and
there is no data demonstrating an association with lower
mortality, therefore this is an arbitrary decision [11].
Measuring serum AED levels may be useful for optimizing
further treatment in patients with epilepsy, but therapeutic
decisions focus primarily on the patient's clinical condition.
Intravenous administration of phenytoin or valproate
should be continued during withdrawal from a barbiturate
coma to prevent recurrence.
Second-line therapy is usually less effective (adult-level A,
one class I RCT test, children-level C, two class III RCTs), and
third-line therapy is signiﬁcantly less effective (adults-level A,
one RCT class I test, children-level U) than initial therapy.
Therefore repeating the second-line treatment with another
drug or anesthetic route (thiopental, midazolam, pentobarbi-
tal, or propofol, all with monitored continuous EEG activity))
should be considered when second-line therapy is ineffective.
Patients can be transferred faster from phase to phase and a
phase can be omitted for patients requiring ICU treatment,
depending on seizure etiology and severity [5,7,26,27].
Under no circumstances should antiepileptic treatment be
stopped in patients previously treated for epilepsy.9. Management of super-refractory SE
Super refractory status epilepticus is deﬁned as ‘‘SE that
continues or recurs 24 h or more after the onset of
anesthesia, including cases in which SE recurs after the
reductionorwithdrawl of anesthesia’’ [11]. Therapy includes
alternative third-line treatment, and is therefore similar to
the management of refractory epilepsy [27]. Other non-
pharmacological treatments include vagus nerve stimula-
tion or surgery such as the removal of the epileptic focus,
hemispherectomy, and callosotomy [37–39]. It is typical to
continue anesthesia for an initial period of 24 h and followed
by a slow reversal. Anesthesia is reestablished if seizures
recur. This pattern of instituting and withdrawing anesthe-
sia is initially continued in 24–48 h cycles and then at 5–7 day
cycles [11].
In addition to anesthesia, a wide range of antiepileptic
drugs including levetiracetam topiramate, oxcarbazepine, and
lacozamide have been used in patients with super-refractory
SE. Whether any is superior is unclear, and it is likely that no
drughas a strikingly different efﬁcacy than any other. However
it is important to consider a combination of two or three
antiepileptic drugs at high doses, without switching too often.
These drugs can be administered at high doses without a
signiﬁcant risk of idiosyncratic reactions [40–45].
Experts agree that new AEDs should be included in the SE
treatment guidelines, due to the increasing number of reports of
AED treatment indicating the efﬁcacy and safety of LEV, TPM,
OCBZ, and LCM for the treatment of resistant SE [5,6,11,22,38–40].
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 1 9 – 4 2 6 425None of these drugs are currently registered in Poland for this
indication.
9.1. Alternative therapeutic options
Immunomodulatory treatments such as steroids, intravenous
immunoglobulins, and plasma replacement are also used in
patientswith refractory SE, sometimes for patientswho do not
have clear evidence of inﬂammatory etiology. It is important to
stress that some cases of NORSE remain undiagnosed, are
presumed to be due autoimmune etiology and in these group
of patients early initiation of immunotherapy could be
beneﬁcial. For steroid therapy, tests are conducted using IV
methylprednisolone at a dose of 1 g for 3 days, and then 1 mg/
kg is continued for approximately 6 weeks. Immunoglobulins
are administered at a dose of 0.4 mg/kg for 5 days, and the
treatment is repeated twice at a 2 weeks interval. Reports are
currently limited to a small group of patients, therefore there
are no standardized recommendations for the use of immu-
nological therapy [15,27,46].(a) Ketamine is an anesthetic frequently described as a
potentially useful therapy, although there are few pub-
lished reports [47]. It has two advantages over the
conventional anesthetics. First, it has no cardiac depres-
sant properties and does not cause hypotension, and it is
potentially neuroprotective because it is a strong N-
methyl-D-aspartate (NMDA) antagonist, although glutami-
nergic damage may already have occurred by the time it is
employed. During prolonged seizures, the numbers and
activities of GABA receptors gradually decrease; thus, the
commonly used ﬁrst-line and second-line antiepileptic
drugs become less effective in long term. Simultaneously,
the numbers and activities of glutamatergic NMDA
receptors increase, often causing refractory status epilep-
ticus and thus providing the possibility of beneﬁcial use of
ketamine to treat SE. Lidocaine and inhaled anesthetics
(isoﬂurane) can also be efﬁcacious in some cases of
refractory SE, however there are no well-deﬁned criteria
to determine when they should be used or their optimal
dosing schedule.(b) Isoﬂurane is administered at 0.8–2 vol%, titrated to obtain
the EEG ‘‘suppression burst’’ pattern. Isoﬂurane may
induce hypotension, atelectasia, paralytic ileus and deep
venous thrombosis.(c) Lidocaine is administered as a 1.5–2 mg/kg as i.v. bolus
(commonly 100 mg in adults), at amaximum rate of 50 mg/
min. A second bolus can be administered if needed.
Lidocaine may induce hypotonia, hallucinations, and
bradyarrhythmias,These drugs should only be adminis-
tered by experienced physicians [15,22,27,47–49].(d) Ketogenic diet for epilepsy has been used for many
decades, especially for children. It is occasionally recom-
mended for people with refractory SE. The effects of a
ketogenic diet treatment can begin after several days or
even weeks [26,46]. However, caveat for ketogenic diet it
requires in many cases a nutritionist as these patients are
often intubated. Furthermore, it requires pharmacist
involvement asmany IV drug solutions or IV ﬂuids contain
dextrose, which must be eliminated to achieve ketosis.(e) Hypothermia is carried out in adults by intravascular
cooling and in children by external cooling to 32–35 degrees
Celsius. It should be emphasized that these reports are all
of a casuistic nature [27,50].10. ConclusionsExperts agree that close and early cooperation with a
neurologist and anesthetist aiming to reduce the risk of
pharmacoresistant cases is an extremely important factor in
the treatment of patients with SE.
The veriﬁcation of the diagnosis at each stage of therapy is
also critically important. The goal of treatment is not only to
relieve the clinical and electrographic features of SE, but also to
prevent the recurrence of epileptic seizures and treat post-
epileptic complications as well as the complications associat-
ed with the treatments used.
Experts emphasize that a lack of effectiveness could be
related to a number of factors, such as insufﬁcient drug doses,
irregular administration, suspension of aggressive treatment,
or early discontinuation of therapy. We hope that these
recommendations at the current stage of theoretical knowledge
and experience will guide treatment to the most optimal form
for taming generalized tonic–clonic SE as quickly as possible.
These recommendations aim to help clinicians understand the
relevant existing evidence for treatment of patients with status
epilepticus and are intended for use by individual clinicians,
hospitals, health authorities, and providers in Poland.
Conﬂict of interestNone declared.
Acknowledgement and ﬁnancial supportNone declared.r e f e r e n c e s
[1] Jędrzejczak J. Objawy kliniczne i postępowanie w stanie
padaczkowym. Przew Lek 2003;6:72–6.
[2] Mazurkiewicz-Bełdzińska M, Szmuda M, Zawadzka M,
Matheisel A. Współczesne leczenie drgawkowego stanu
padaczkowego — algorytm leczenia i przegląd
piśmiennictwa. Anestezjologia Intensywna Terapia
2014;46:309–17.
[3] Rejdak K. Współczesne algorytmy diagnostyczne i
standardy terapeutyczne w nowo rozpoznanej padaczce u
dorosłych. Polski Przegląd Neurologiczny 2010;3:131–3.
[4] Szklener S, Godek M, Korchut A, Balicka-Adamik L, Rejdak R,
Rossetti AO, et al. Outcome prediction in patients with acute
repetitive seizures: application of the Status Epilepticus
Severity Score. Epilepsia 2018;59(May (5)):e68–72.
[5] Meierkord H, Boon P, Gocke K, Shorvon S, Tinuper S,
Holtkamp M. EFNS guidelines on the management of status
epilepticus in adults. Eur J Neur 2010;17:348–55.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 1 9 – 4 2 6426[6] Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R,
Bainbridge J, et al. Evidence-based guideline: treatment of
convulsive status epilepticus in children and adults: Report
of the Guideline Committee of the American Epilepsy
Society. Epilepsy Curr 2016;16:48–61.
[7] Trinka E, Cock H, Hesdorffer D. A deﬁnition and
classiﬁcation of SE – report of the ILAE task force on
classiﬁcation of status epilepticus. Epilepsia 2015;56:1515–
23.
[8] Commission on classiﬁcation and terminology of the
International League Against Epilepsy: proposal for revised
clinical and electroencephalograpihic classiﬁcation of
epileptic seizures. Epilepsia 1981;22:489–501.
[9] Jenssen S, Gracely E, Sperling M. How long do most seizures
last? A systematic comparison of seizures recorded in the
epilepsy monitoring unit. Epilepsia 2006;47:1499–503.
[10] Lowenstein D, Bleck T, Macdonald R. It's time to revise the
deﬁnition of status epilepticus. Epilepsia 1999;40:120–2.
[11] Shorvon S. Super-refractory status epilepticus: an approach
to therapy in this difﬁcult clinical situation. Epilepsia
2011;52:53–6.
[12] Shorvon SD, Ferlisi M. The treatment of super-refractory
status epilepticus: a critical review of available therapies
and a clinical treatment protocol. Brain 2011;134:2802–18.
[13] Sanchez S, Rincon F. Status epilepticus: epidemiology and
public health needs. J Clin Med 2016;5(8). http://dx.doi.org/
10.3390/jcm5080071
[14] Millikan D, Rice B, Silbergleit R. Emergency treatment of
status epilepticus: current thinking. Emerg Med Clin North
Am 2009;27:101–13.
[15] Rossetti A. Treatment options in the management of status
epilepticus. Curr Treat Options Neurol 2010;12:100–12.
[16] Novy J, Logroscino G, Rosetti A. Refractory status
epilepticus: a prospective observational study. Epilepsia
2010;51:251–6. http://dx.doi.org/10.1111/j.1528-1167.2009.
02323.x
[17] Raspall-Chaure M, Chin R, Neville B, Bedford H, Scott RC.
The epidemiology of convulsive status epilepticus in
children: a critical review. Epilepsia 2007;48:1652–63.
[18] DeLorenzo RJ, Kirmani B, Deshpande LS, Jakkampudi V,
Towne AR, Waterhouse E, et al. Comparisons of the
mortality and clinical presentations of status epilepticus in
private practice community and university hospital
settings in Richmond, Virginia. Seizure 2009;18(July (6)):405–
11. http://dx.doi.org/10.1016/j.seizure.2009.02.005
[19] Shearer P, Riviello J. Generalised convulsive status
epilepticus in adults and children: treatment guidelines
and protocols. Emerg Med Clin North Am 2011;29:51–64.
[20] Koubeissi M, Alshekhlee A. In-hospital mortality of
generalized convulsive status epilepticus – a large US
sample. Neurology 2007;69:886–93.
[21] Wylie T, Murr N. Status epilepticus. StatPearls. Treasure
Island, FL: StatPearls Publishing; 2017, February.
[22] Brophy G, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser
T, et al. Guidelines for the evaluation and management of
status epilepticus. Neurocrit Care 2012;17:3–23.
[23] Rajshekher G. Recent trends in the management of status
epilepticus. Indian J Crit Care Med 2005;9:52–63.
[24] Browne T. The pharmacokinetics of agents used to treat
status epilepticus. Neurol 1990;40:28–32.
[25] Turner C. The management of tonic–clonic status
epilepticus. Curr Anaesth Crit Care 2007;18:86–93.
[26] Chen J, Wasterlain C. Status epilepticus: pathophysiology
and management in adults. Lancet Neurol 2006;5:246–56.
[27] Shorvon S, Ferlisi M. The outcome of therapies in refractory
and super-refractory convulsive status epilepticus and
recommendations for therapy. Brain 2012;135:2314–28.[28] Alldredge B, Wall D, Ferriero D. Effect of prehospital
treatment on the outcome of status epilepticus in children.
Pediatr Neurol 1995;12:213–6.
[29] Hirsch L. Intramuscular versus intravenous
benzodiazepines for prehospital treatment of status
epilepticus. New Engl J Med 2012;7:659–60.
[30] Lowenstein D, Alldredge B, Allen F, Neuhaus J, Corry M,
Gottwald M, et al. The prehospital treatment of status
epilepticus (PHTSE) study: design and methodology.
Control Clin Trials 2001;22:290–309.
[31] Martland T, Harris C. Management of status epilepticus.
Paediatr Child Health 2009;19:225–31.
[32] Treiman D, Meyers P, Walton N. A comparison of four
treatments for generalized convulsive status epilepticus.
Veterans affairs status epilepticus cooperative study group.
New Engl J Med 1998;339:792–8.
[33] Popławska M, Borowicz KK, Czuczwar SJ. The safety and
efﬁcacy of fosphenytoin for the treatment of status
epilepticus. Expert Rev Neurother 2015;15:983–92.
[34] Trinka E, Höﬂer J, Leitinger M, Brigo F. Pharmacotherapy for
status epilepticus. Drugs 2015;75:1499–521.
[35] Shorvon S. Status epilepticus: its clinical features and
treatment in children and adults. Cambridge: Cambridge
University Press; 1994.
[36] Lyer V, Hoel R, Rabinstein A. Propofol infusion syndrome in
patients with refractory status epilepticus: an 11-year
clinical experience. Crit Care Med 2009;37:3024–30.
[37] De Herdt V, Waterschoot I, Vonck K. Vagus nerve
stimulation for refractory status epilepticus. Eur J Paediatr
Neurol 2009;13:286–9.
[38] Lhatoo S, Alexopoulos A. The surgical treatment of status
epilepticus. Epilepsia 2007;48(Supply 8):61–5.
[39] Bhatia S, Ahmad F, Miller I, Ragheb J, Morrison G, Jayakar P,
et al. Surgical treatment of refractory status epilepticus in
children. J Neurosurg Pediatr 2013;12:360–6.
[40] Yasiry Z, Shorvon S. The relative effectiveness of ﬁve
antiepileptic drugs in treatment of benzodiazepine-
resistant convulsive status epilepticus: a meta-analysis of
published studies. Seizure 2014;33:167–74.
[41] Knake S, Gruener J, Hattemer K. Intravenous levetiracetam
in the treatment of benzodiazepine refractory status
epilepticus. J Neurol Neurosurg Psychiatry 2008;79:588–9.
[42] Ruegg S, Naegelin Y, Hardmeier M. Intravenous
levetiracetam: treatment experience with the ﬁrst 50
critically ill patients. Epilepsy Behav 2008;12:477–80.
[43] Towne A, Garnett L, Waterhouse E, Morton LD, DeLorenzo
RJ. The use of topiramate in refractory status epilepticus.
Neurol 2003;60:332–4.
[44] Kellinghaus C, Berning S, Stogbauer F. Use of oxcarbazepine
for treatment of refractory status epilepticus. Seizure
2014;23:151–4.
[45] Robakis T, Hirsch L. Literature review, case report and
expert discussion of prolonged refractory status
epilepticus. Neurocrit Care 2006;4:35–46.
[46] Walker D, Teach S. Update on the acute management of
status epilepticus in children. Curr Opin Pediatr
2006;18:239–44.
[47] Pruss H, Holtkamp M. Ketamine successfully terminates
malignant. Epilepsy Res 2008;62:1428–31.
[48] Mirsattari S, Sharpe M, Young G. Treatment of refractory
status epilepticus with inhalational anesthetic agents
isoﬂurane and desﬂurane. Arch Neurol 2004;60:1254–9.
[49] Iannetti P, Spalice A, Parisi P. Calcium channel blocker
verapamil administration in prolonged and refractory
status epilepticus. Epilepsia 2005;46:967–9.
[50] Corry J, Dhar R, Murphy T, Diringer M. Hypothermia for
refractory status epilepticus. Neurocrit Care 2008;9:189–97.
